{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:10:01Z","timestamp":1773148201728,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,1,10]],"date-time":"2010-01-10T00:00:00Z","timestamp":1263081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00223-009-9329-4","type":"journal-article","created":{"date-parts":[[2010,1,9]],"date-time":"2010-01-09T02:00:27Z","timestamp":1263002427000},"page":"202-210","source":"Crossref","is-referenced-by-count":71,"title":["Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications"],"prefix":"10.1007","volume":"86","author":[{"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Rabenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry-Jean","family":"Gathon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Ethgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,10]]},"reference":[{"key":"9329_CR1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487\u2013497","journal-title":"N Engl J Med"},{"key":"9329_CR2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hec.609","volume":"10","author":"DA Hughes","year":"2001","unstructured":"Hughes DA, Bagust A, Haycox A, Walley T (2001) The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 10:601\u2013615","journal-title":"Health Econ"},{"key":"9329_CR3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0168-8510(01)00178-6","volume":"59","author":"I Cleemput","year":"2002","unstructured":"Cleemput I, Kesteloot K, DeGeest S (2002) A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 59:65\u201394","journal-title":"Health Policy"},{"key":"9329_CR4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1524-4733.2007.00205.x","volume":"10","author":"D Hughes","year":"2007","unstructured":"Hughes D, Cowell W, Koncz T, Cramer J (2007) Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 10:498\u2013509","journal-title":"Value Health"},{"key":"9329_CR5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"key":"9329_CR6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","volume":"19","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811\u2013818","journal-title":"Osteoporos Int"},{"key":"9329_CR7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"9329_CR8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","volume":"17","author":"D Weycker","year":"2006","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645\u20131652","journal-title":"Osteoporos Int"},{"key":"9329_CR9","first-page":"1","volume":"843","author":"World Health Organization","year":"1994","unstructured":"World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1\u2013129","journal-title":"World Health Organ Tech Rep Ser"},{"key":"9329_CR10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44\u201347","journal-title":"Value Health"},{"key":"9329_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1524-4733.2008.00469.x","volume":"12","author":"I Cleemput","year":"2009","unstructured":"Cleemput I, van Wilder P, Huybrechts M, Vrijens F (2009) Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 12:441\u2013449","journal-title":"Value Health"},{"key":"9329_CR12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bone.2008.08.119","volume":"43","author":"M Hiligsmann","year":"2008","unstructured":"Hiligsmann M, Bruyere O, Ethgen O, Gathon HJ, Reginster JY (2008) Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 43:991\u2013994","journal-title":"Bone"},{"key":"9329_CR13","first-page":"942","volume":"79","author":"JY Reginster","year":"2001","unstructured":"Reginster JY, Gillet P, Gosset C (2001) Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ 79:942\u2013946","journal-title":"Bull World Health Organ"},{"key":"9329_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6290","volume":"6","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1\u2013146","journal-title":"Health Technol Assess"},{"key":"9329_CR15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF01623689","volume":"7","author":"O Johnell","year":"1997","unstructured":"Johnell O, Gullberg B, Kanis JA (1997) The hospital burden of vertebral fracture in Europe: a study of national register sources. Osteoporos Int 7:138\u2013144","journal-title":"Osteoporos Int"},{"key":"9329_CR16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989\u2013995","journal-title":"Osteoporos Int"},{"key":"9329_CR17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1302\/0301-620X.80B2.7762","volume":"80","author":"BR Singer","year":"1998","unstructured":"Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80:243\u2013248","journal-title":"J Bone Joint Surg Br"},{"key":"9329_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s001980050113","volume":"9","author":"LJ Melton 3rd","year":"1999","unstructured":"Melton LJ 3rd, Crowson CS, O\u2019Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29\u201337","journal-title":"Osteoporos Int"},{"key":"9329_CR19","volume-title":"D\u00e9mographie math\u00e9matique. Tables de mortalit\u00e9 2004 et 2002\u20132004","author":"Institut National de Statistique","year":"2006","unstructured":"Institut National de Statistique (2006) D\u00e9mographie math\u00e9matique. Tables de mortalit\u00e9 2004 et 2002\u20132004. Direction G\u00e9n\u00e9rale Statistique et Information Economique, Belgique"},{"key":"9329_CR20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s001980050105","volume":"8","author":"A Oden","year":"1998","unstructured":"Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599\u2013603","journal-title":"Osteoporos Int"},{"key":"9329_CR21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108\u2013112","journal-title":"Osteoporos Int"},{"key":"9329_CR22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468\u2013473","journal-title":"Bone"},{"key":"9329_CR23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2165\/00019053-199915050-00008","volume":"15","author":"JY Reginster","year":"1999","unstructured":"Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de Froidmont C, Gosset C (1999) Direct costs of hip fractures in patients over 60\u00a0years of age in Belgium. Pharmacoeconomics 15:507\u2013514","journal-title":"Pharmacoeconomics"},{"key":"9329_CR24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s001980070102","volume":"11","author":"P Autier","year":"2000","unstructured":"Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC, Boonen S (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373\u2013380","journal-title":"Osteoporos Int"},{"key":"9329_CR25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00296-006-0180-x","volume":"26","author":"S Bouee","year":"2006","unstructured":"Bouee S, Lafuma A, Fagnani F, Meunier PJ, Reginster JY (2006) Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int 26:1063\u20131072","journal-title":"Rheumatol Int"},{"key":"9329_CR26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s001980200033","volume":"13","author":"SE Gabriel","year":"2002","unstructured":"Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ 3rd (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323\u2013330","journal-title":"Osteoporos Int"},{"key":"9329_CR27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00198-003-1385-4","volume":"14","author":"LJ Melton 3rd","year":"2003","unstructured":"Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383\u2013388","journal-title":"Osteoporos Int"},{"key":"9329_CR28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","volume":"82","author":"M Hiligsmann","year":"2008","unstructured":"Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82:288\u2013292","journal-title":"Calcif Tissue Int"},{"key":"9329_CR29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1524-4733.2008.00497.x","volume":"12","author":"M Hiligsmann","year":"2009","unstructured":"Hiligsmann M, Ethgen O, Bruy\u00e8re O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687\u2013696","journal-title":"Value Health"},{"key":"9329_CR30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00198-009-0924-z","volume":"21","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157\u2013165","journal-title":"Osteoporos Int"},{"key":"9329_CR31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S8756-3282(00)00381-1","volume":"27","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585\u2013590","journal-title":"Bone"},{"key":"9329_CR32","unstructured":"National Institute for Health and Clinical Excellence (2008) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Available via DIALOG at: http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA161guidanceword.pdf . Accessed 15 June 2009"},{"key":"9329_CR33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","volume":"137","author":"SL Greenspan","year":"2002","unstructured":"Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875\u2013883","journal-title":"Ann Intern Med"},{"key":"9329_CR34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","volume":"103","author":"JL Stock","year":"1997","unstructured":"Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291\u2013297","journal-title":"Am J Med"},{"key":"9329_CR35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00198-007-0349-5","volume":"18","author":"O Strom","year":"2007","unstructured":"Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries\u2014an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047\u20131061","journal-title":"Osteoporos Int"},{"key":"9329_CR36","unstructured":"Belgian Centre for Pharmacotherapeutic Information (2009). Available via DIALOG at: http:\/\/www.cbip.be\/GGR\/MPG\/MPG_NI.cfm#MP_04090 . Accessed 15 June 2009"},{"key":"9329_CR37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"J Kanis","year":"2008","unstructured":"Kanis J, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399\u2013428","journal-title":"Osteoporos Int"},{"key":"9329_CR38","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00198-007-0410-4","volume":"18","author":"F Lekkerkerker","year":"2007","unstructured":"Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D, Hughes N, Kaufman JM, Korte S, Kreutz G, Laslop A, Mitlak B, Rabenda V, Rizzoli R, Santora A, Schimmer R, Tsouderos Y, Viethel P, Reginster JY (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311\u20131317","journal-title":"Osteoporos Int"},{"key":"9329_CR39","volume-title":"Modelling methods for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K (2006) Modelling methods for health economic evaluation. Oxford University Press, New York"},{"key":"9329_CR40","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3\u2013S13","journal-title":"Am J Med"},{"key":"9329_CR41","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1359\/jbmr.080418","volume":"23","author":"JR Curtis","year":"2008","unstructured":"Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435\u20131441","journal-title":"J Bone Miner Res"},{"key":"9329_CR42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0272989X08318461","volume":"29","author":"FE Cotte","year":"2009","unstructured":"Cotte FE, Fautrel B, De Pouvourville G (2009) A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Making 29:125\u2013139","journal-title":"Med Decis Making"},{"key":"9329_CR43","first-page":"135","volume":"35","author":"P Sambrook","year":"2006","unstructured":"Sambrook P (2006) Compliance with treatment in osteoporosis patients\u2014an ongoing problem. Aust Fam Phys 35:135\u2013137","journal-title":"Aust Fam Phys"},{"key":"9329_CR44","unstructured":"International Osteoporosis Foundation (2009) Adherence. Available via DIALOG at: http:\/\/www.iofbonehealth.org\/health-professionals\/about-osteoporosis\/adherence.html . Accessed 15 June 2009"},{"key":"9329_CR45","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296\u20131310","journal-title":"Clin Ther"},{"key":"9329_CR46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023\u20131031","journal-title":"Osteoporos Int"},{"key":"9329_CR47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00198-008-0651-x","volume":"20","author":"C Roerholt","year":"2009","unstructured":"Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299\u2013307","journal-title":"Osteoporos Int"},{"key":"9329_CR48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-008-0644-9","volume":"20","author":"O Strom","year":"2009","unstructured":"Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23\u201334","journal-title":"Osteoporos Int"},{"key":"9329_CR49","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"9329_CR50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjmed.2006.03.029","volume":"120","author":"MA Brookhart","year":"2007","unstructured":"Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251\u2013256","journal-title":"Am J Med"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-009-9329-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-009-9329-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-009-9329-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T07:37:57Z","timestamp":1558683477000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-009-9329-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,10]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["9329"],"URL":"https:\/\/doi.org\/10.1007\/s00223-009-9329-4","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,10]]}}}